media – Page 160 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Surgical equipment company completes new round of strategic financing

According to the Medicine Intelligence Data Investment Pattern Database, surgical equipment company Nuomei Xinchuang Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as Nuomei Xinchuang) recently announced that it has successfully completed a new round of strategic financing, with a total financing amount of over 300 million yuan. This round of financing is led by Qiming Venture Capital and co invested by Sunshine Ronghui Capital. Star Bridge Capital serves as the exclusive financial advisor. It is reported that the funds raised in this round will provide important financial support for the market expansion and product research and development of Nuomei Xinchuang, further helping the company to continue leading the field of ear, nose, throat, and cranial spine surgical instruments. It is worth mentioning that according to the Medicine Intelligence Data Investment Pattern Database, this financing is the first financing for Novo Medical after its official name change. Its predecessor, Leno ...
- Source: drugdu
- 261
- February 18, 2025
MyPlex withdraws IPO application, financial data was once accused of having 386 million yuan in errors

On February 16, the Shenzhen Stock Exchange issued a decision to terminate the review of the initial public offering and listing of Yantai MyPlex International Biopharmaceutical Co., Ltd. (hereinafter referred to as MyPlex) on the Growth Enterprise Market. Previously, MyPlex’s IPO application was accepted on September 28, 2022, and passed the meeting on June 16, 2023, but the company finally chose to withdraw its application due to failure to submit registration materials within the prescribed time. According to the information, MyPlex was established in 2013 and is a CDMO (contracted research and development and production of pharmaceuticals) company focusing on the field of biopharmaceuticals, focusing on providing CDMO services for monoclonal antibodies, bispecific antibodies, polyspecific antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins and other biopharmaceuticals. The reporter of “Daily Economic News” noticed that MyBio was found to have major errors in its application materials during the first round ...
- Source: drugdu
- 259
- February 18, 2025
Innovent Biologics’ PD-1 bispecific antibody is again granted FDA Fast Track Qualification

On February 17, Innovent Biologics announced that its PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 was granted Fast Track Qualification (FTD) by the US FDA, with the proposed indication being locally advanced or metastatic squamous non-small cell lung cancer that has progressed after anti-PD-(L)1 immune checkpoint inhibitors and platinum-containing chemotherapy. This is the second time that IBI363 has been granted FDA Fast Track Qualification after melanoma. According to the data, IBI363 is the world’s first PD-1/IL-2 bispecific fusion protein independently developed by Innovent Biologics, which has the functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. IBI363 has shown positive efficacy and safety signals in a variety of advanced solid tumors. Innovent Biologics is currently conducting Phase 1/2 clinical studies of IBI363 in China and the United States. https://finance.eastmoney.com/a/202502183321598760.html
- Source: drugdu
- 282
- February 18, 2025
AI medical concept continues to be strong, Meinian Health has 5 boards in 7 days

On February 17, AI medical concept stocks continued to be hot in the capital market. Meinian Health has 5 boards in 7 days, Anping has 20CM for two consecutive days, Saili Medical has 5 boards in 10 days, Jiahe Meikang, Xin Ganjiang, Sichuang Yihui, and Chaoyan shares have risen by more than 10%. Some popular concept stocks have also successively issued announcements on abnormal stock trading fluctuations. For example, Meinian Health announced on February 16 that the company’s current business situation is normal, and there has been no major changes in the internal and external business environment. After verification, the company and the actual controller have no major matters that should be disclosed but have not been disclosed or major matters in the planning stage. Anping issued an announcement on February 17, saying that the company has recently noticed that many media reported that Huawei Technologies Co., Ltd. will build ...
- Source: drugdu
- 233
- February 18, 2025
The epidemic of acute respiratory infectious diseases in my country continues to decline

According to CCTV News on February 17, the National Health Commission held a press conference to introduce the seasonal solar terms and health-related situations. Media reports that influenza viruses are still prevalent in some countries and regions recently. What is the current monitoring situation of respiratory infectious diseases such as influenza in my country? Peng Zhibin, a researcher at the Chinese Center for Disease Control and Prevention, introduced that the current monitoring results indicate that the epidemic of acute respiratory infectious diseases in my country continues to decline. Among them, influenza virus is the main pathogen causing recent acute respiratory infections. It is still in the seasonal epidemic period, but the overall epidemic intensity is on a downward trend; there are differences in the level of influenza activity in the north and south. In the sixth week, the south was higher than the north. The positive rates of Mycoplasma pneumoniae ...
- Source: drugdu
- 249
- February 18, 2025
Ethiopia MEDEXPO

Organiser：EXPOGROUP Exhibition Company Time：March 6th – 8th, 2025 Address：2Q56+MVV, Addis Ababa, Ethiopia Exhibition hall：Addis Ababa Exhibition Center Product range: Medical Equipment: Anesthetic equipment, respiratory devices, imaging equipment, blood pressure devices, diagnostic instruments and apparatus, dialysis equipment, electro (high-frequency) therapy, surgical instruments, electroencephalographs, electrocardiograph (ECG) equipment and accessories, ultraviolet and infrared radiation equipment, laboratory supplies, ultrasound diagnostic equipment, cardiac catheterization equipment, infusion technology equipment, MRI scanning devices, laser therapy, surgical equipment, etc. Dental Equipment: Dental instruments and equipment, maintenance and repair, filling materials, radiological equipment and products, sterilization systems, dental care products. Optical Equipment: Optical eye examination devices, optical and sunglasses frames, lens frames and manufacturing equipment and accessories, optical instruments and components. Healthcare Products: Medical herbal preparations, food supplements, vitamins and minerals, dietary and nutritional products, personal hygiene products, homeopathic preparations, dermatological preparations, mother and baby care, infant food, fitness equipment, and other healthcare-related items. About Ethiopia MEDEXPO： ...
- Source: drugdu
- 676
- February 18, 2025
How AI Procurement Can Boost Supply Chain Efficiency by 50% in the Pharmaceutical Industry? Drugdu AI is Exploring the Future!

Traditional procurement faces high costs, lack of supply chain transparency, and complex compliance processes. Drugdu AI is developing intelligent procurement solutions to make pharmaceutical B2B purchasing more efficient and smarter! What is Drugdu AI? Drugdu AI is a leading B2B pharmaceutical procurement platform that has built a global database of pharmaceutical suppliers. By leveraging AI-driven decision-making and data-powered supply chain optimization, Drugdu AI aims to enhance matching accuracy and reduce procurement risks. Drugdu AI’s Core Capabilities 1. Global B2B Pharmaceutical Trading Platform Drugdu.com has built a digital procurement ecosystem covering pharmaceuticals, medical devices, and pharmaceutical raw materials. It seamlessly connects manufacturers, suppliers, and buyers worldwide, facilitating efficient cross-border transactions. 2. Intelligent Supply Chain Solutions The platform provides end-to-end services, including precise supplier matching, real-time price transparency, international logistics optimization, and inventory management—significantly shortening procurement cycles and reducing transaction costs. 3. Integrated Compliance & Certification Support Drugdu AI integrates FDA, GMP, ...
- Source: drugdu
- 687
- February 18, 2025
AI DeepSeek Drugdu AI intelligent procurement solutions pharma
Beilu Pharmaceutical’s compound polyethylene glycol electrolyte powder (III) has been approved for registration

February 14, 2025 10:26 Author: Chen Xi Source: Shanghai Securities Journal · China Securities Network On the evening of February 13th, Beilu Pharmaceutical announced that it had successfully received the Drug Registration Certificate for Compound Polyethylene Glycol Electrolyte Powder (III) approved and issued by the National Medical Products Administration. This drug belongs to Class 4 of chemical drugs and is considered to have passed the quality and efficacy consistency evaluation of generic drugs. Compound polyethylene glycol electrolyte powder, as a commonly used intestinal cleansing and penetrating laxative in clinical practice, has a broad market demand. According to data from MineNet, in 2023, its terminal sales in public medical institutions in China exceeded 1.3 billion yuan, and compound polyethylene glycol electrolyte powder (III) has been included in the tenth batch of national centralized drug procurement. This approval further enriches the product pipeline of Beilu Pharmaceutical in the field of digestive system ...
- Source: drugdu
- 571
- February 17, 2025
The 10th Batch of Centralized Procurement Promotes Continuous Improvement in Demand for Borosilicate Pharmaceutical Glass

Guolian Minsheng Securities has released a special research report on the building materials industry. The tenth batch of national drug procurement bidding will be held in December 2024, involving 62 drug varieties and 263 product specifications, all of which are drugs that have passed the patent period, produced by multiple enterprises, and have sufficient competition, covering key areas such as hypertension and tumors. 385 products from 234 enterprises have obtained the qualification for selection, and all selected drugs have passed the evaluation of quality and efficacy consistency. The tenth batch of centralized procurement is expected to commence in April 2025. The centralized procurement of up to ten batches is the core driving force for the increase in boron silicon permeability in medicinal glass The consumption structure of drugs in China is mainly dominated by generic drugs, and in the past, generic drugs have dominated through centralized procurement. In fact, the ...
- Source: drugdu
- 230
- February 17, 2025
【EXPERT Q&A】Medical devices nationwide collection price, long-term, what impact will it have on the industry?

Drugdu.com expert’s response: The nationwide centralized procurement and price reduction of medical devices will have profound and multifaceted impacts on the industry in the long run. Below is a detailed analysis of these impacts: I. Promoting Market Competition and Optimizing Supply Chain Management Intensified Market Competition: The centralized procurement and price reduction policy significantly lowers the prices of medical devices through volume-for-price exchanges, making market competition fiercer. To maintain market share and profitability, enterprises must strengthen product research and development (R&D), innovation, and improve product quality and cost-effectiveness. Optimized Supply Chain Management: The centralized procurement policy urges enterprises to optimize their supply chain management, reducing inventory pressure, enhancing supply efficiency, and lowering the circulation costs of medical devices. This helps enterprises improve operational efficiency, reduce costs, and thereby strengthen their market competitiveness. II. Facilitating Industry Transformation and Upgrade, as well as Domestic Substitution Driving Industry Transformation and Upgrade: Facing the ...
- Source: drugdu
- 450
- February 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.